Biopharmaceutical entrepreneurship in two Japanese and French bioclusters: differences in founder profiles and experience

Eric Jolivet, Caroline Lanciano-Morandat (), Hiroatsu Nohara and Daniel Pardo
Additional contact information
Eric Jolivet: CRM - Centre de Recherche en Management - UT Capitole - Université Toulouse Capitole - UT - Université de Toulouse - IAE - Institut d'Administration des Entreprises - Toulouse - CNRS - Centre National de la Recherche Scientifique
Caroline Lanciano-Morandat: LEST - Laboratoire d'Economie et de Sociologie du Travail - AMU - Aix Marseille Université - CNRS - Centre National de la Recherche Scientifique
Daniel Pardo: LEST - Laboratoire d'Economie et de Sociologie du Travail - AMU - Aix Marseille Université - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: Favoured by genetic engineering breakthroughs, a new type of firm has emerged in the pharmaceutical industry. New Biotechnology Firms (NBFs) are ‘bridging institutions', accelerating the commercialisation of science from academia to the pharmaceutical market and facilitating technological incursions into drug development or therapeutic paths yet unexplored. As such, they have raised industrial and political interest around the world. Successes can be outstanding and some countries seem to offer much more favourable environments than others. Countries' performances are usually benchmarked against their provision of favourable resources and institutions, but this article takes an alternative route by considering the entrepreneurial side of NBF as a major factor in their emergence. ‘Entrepreneur biographies' and firm creation experience were collected in two comparable bioclusters in France (Evry) and Japan (Kobe), on 11 Japanese and French drug development NBFs. The result shows an interesting variation in backgrounds and motivations, in that almost all our French entrepreneurs came from public research institutes, whereas a large share of the Japanese entrepreneurs came from large pharmaceutical companies. This finding questions the universal nature of entrepreneurship in biopharmaceutical firms and invites consideration for a model of entrepreneurship that is socially embedded in a country's specific institutional and historical factors.

Keywords: high-tech entrepreneurship; professions and careers; innovation systems; societal and institutional change; university–industry relations; international comparisons (search for similar items in EconPapers)
Date: 2009
Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-00424901v1
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Published in Asian Business and Management, 2009, 8 (4), pp.429-460

Downloads: (external link)
https://shs.hal.science/halshs-00424901v1/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-00424901

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().